Skip to main content
. 2020 Mar 27;12(4):801. doi: 10.3390/cancers12040801

Figure 4.

Figure 4

ADAMTS1 inhibition compromises the stemness capacities and endothelial-like phenotype in tumor xenografts. (a–c) Graphs representing mRNA fold change expression of NANOG, POU5F1, PROM1 and SOX2 (a), ADAMTS1 (b) and CDH5 (c), in MUM-2B WT 2D cultured cells and NSG xenografts (n = 4–6 for cells and n = 3–4 for NSG); (d-e) Graphs representing mRNA fold change expression of NANOG, POU5F1, PROM1 and SOX2 (d), and CDH5 (e) in NSG xenografts generated with WT and ATS1-KO cells (n = 3 for WT, n = 5 for ATS1-KO1 and n = 4–6 for ATS1-KO2); (f) Representative images of IF analysis of WT and ATS1-KO NSG xenografts, at low and high magnification. For low magnification, columns from left to right: CDH5, EMCN, DAPI and merge; (g) Representative images of IHC staining of CDH5 and NANOG in consecutive sections of WT and ATS1-KO NSG xenografts; (h) Representative images of IHC co-staining of CDH5 and PAS, in WT and ATS1-KO NSG xenografts. (****, p < 0.0001; **, p < 0.01; and *, p < 0.05. White scale bar = 50 µm).